Welcome to our dedicated page for Beam Therapeutics news (Ticker: BEAM), a resource for investors and traders seeking the latest updates and insights on Beam Therapeutics stock.
Beam Therapeutics Inc. (BEAM) is a pioneering biotechnology company developing precision genetic medicines through its innovative base editing platform. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments in gene editing technology.
Investors and researchers will find curated press releases covering therapeutic advancements, financial disclosures, and scientific partnerships. Our collection includes updates on BEAM's hematology programs, in vivo editing initiatives, and manufacturing capabilities - all essential for understanding the company's position in genetic medicine.
Key content categories include clinical trial progress for sickle cell disease therapies, intellectual property developments in base editing, and strategic collaborations advancing CRISPR-based treatments. Each update is carefully verified to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for direct access to Beam Therapeutics' latest milestones in creating single-edit genetic therapies. Check regularly for authoritative updates on one of biotechnology's most promising precision medicine platforms.
Beam Therapeutics reported key developments and a net loss of $72.0 million for Q2 2022, or $1.02 per share. The company ended the quarter with $1.2 billion in cash, supporting its clinical pipeline, including the BEACON Phase 1/2 trial for BEAM-101 in sickle cell disease, set to begin enrollment in H2 2022. However, the FDA placed a clinical hold on BEAM-201's IND submission for T-cell malignancies. Beam appointed John Lo as Chief Commercial Officer to enhance its commercialization strategy and is advancing several programs, including BEAM-301 for glycogen storage disease.
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will participate in a panel at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 9, 2022, at 9:45 a.m. ET. The panel is titled "So Let it Be (Re)Written - Updates in Gene Modulation." Interested parties can access a live webcast on the investor section of Beam's website, which will be archived for 60 days post-event. Beam is focused on precision genetic medicines, utilizing proprietary base editing technology to advance its therapeutic programs.
Beam Therapeutics (Nasdaq: BEAM) announced that the FDA placed its BEAM-201 Investigational New Drug application for treating T-cell acute lymphoblastic leukemia on clinical hold as of July 29, 2022. The FDA plans to issue an official letter within 30 days. Beam Therapeutics is focused on precision genetic medicines using base editing technology. The company aims to advance innovative therapeutic strategies while also building internal manufacturing capabilities.
Beam Therapeutics (Nasdaq: BEAM) announced the presentation of new research on improved transplant conditioning regimens for sickle cell disease (SCD) patients at the FASEB Genome Engineering Conference on June 27, 2022. Led by Nicole Gaudelli, Ph.D., the findings focus on two ex vivo base editing programs, BEAM-101 and BEAM-102. These programs aim to enhance patient safety by developing a non-genotoxic conditioning approach using antibody-based therapy. Beam plans to initiate patient enrollment for BEAM-101 and submit an investigational new drug application for BEAM-102 in late 2022.
Beam Therapeutics (Nasdaq: BEAM) will have CEO John Evans engage in a fireside chat during the 2022 Jefferies Healthcare Conference on June 10, 2022, at 9:30 a.m. ET in New York City. The event will be accessible via a live webcast on the company's website, with a recording available for 60 days post-event. Beam is dedicated to pioneering precision genetic medicines using its base editing technology, aimed at providing lifelong cures for serious diseases through precise genomic editing.
Beam Therapeutics (Nasdaq: BEAM) reported Q1 2022 financial results, ending with $1.2 billion in cash, cash equivalents, and marketable securities. The company is on track to enroll patients in the BEACON-101 clinical trial and submit IND applications for BEAM-102 and BEAM-201 in the second half of 2022. Beam has initiated a natural history study on sickle cell trait, partnering with the NASCC. R&D expenses decreased to $65.4 million from $190.1 million year-over-year. The net loss improved to $69.2 million from $201.6 million in Q1 2021.
Beam Therapeutics (Nasdaq: BEAM), a biotech firm focused on precision genetic medicines, announced CEO John Evans will speak at two investor conferences in May 2022. The events are the BofA Securities 2022 Healthcare Conference on May 11, at 2:00 PM PT in Las Vegas, and the RBC Capital Markets Global Healthcare Conference on May 17, at 2:35 PM ET in NYC. Live webcasts will be available on their website and archived for 60 days. Beam is advancing gene editing technologies, particularly base editing, to develop therapies for serious diseases.
Beam Therapeutics (Nasdaq: BEAM) announced it will present new preclinical data at the ASGCT Annual Meeting from May 16-19, 2022. The findings focus on the BEAM-301 program for glycogen storage disease type Ia (GSDIa) and a base editing program for alpha-1 antitrypsin deficiency. Data indicate that BEAM-301 demonstrates significant liver editing improvements, enhancing metabolic parameters and survival in mouse models. Additionally, Beam's proprietary lipid nanoparticle (LNP) technology shows promise for delivering mRNA to immune cells, offering potential advancements in immunology and oncology.
Beam Therapeutics (Nasdaq: BEAM) announced its participation in a fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 1, 2022, at 9:00 a.m. ET. CEO John Evans and Chief Scientific Officer Giuseppe Ciaramella will represent the company. A live webcast will be accessible in the investor section of Beam's website and will be available for 60 days post-event. Beam Therapeutics specializes in precision genetic medicines through base editing, enabling efficient genomic alterations without DNA breaks, supporting its mission to provide lifelong cures.
Beam Therapeutics (Nasdaq: BEAM) will have its president and chief scientific officer, Giuseppe Ciaramella, Ph.D., participate in a fireside chat at the Barclays 2022 Global Healthcare Conference. The event is scheduled for March 15, 2022, at 8:30 a.m. ET, in Miami, FL. A live webcast of the discussion will be available on the company’s investor website and will be archived for 60 days. Beam is focused on precision genetic medicines using its unique base editing technology to develop innovative therapies for serious diseases.
FAQ
What is the current stock price of Beam Therapeutics (BEAM)?
What is the market cap of Beam Therapeutics (BEAM)?
